Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.16 - $46.48
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.23M
Market Cap
$5.55B
Enterprise Value$5.85B
Total Cash (Recent Filing)$276.24M
Total Debt (Recent Filing)$254.58M
Price to Earnings (P/E)95.1
Beta1.31
Next Earnings
Oct 30, 2025EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding158,665,620
10 Day Avg. Volume2,176,046
30 Day Avg. Volume2,231,287
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue15.15
Enterprise Value/Gross Profit17.32
Enterprise Value/Ebitda83.54
Forecast
1Y Price Target
$38.25Price Target Upside7.53% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Market ExpansionBriumvi is now commercially available in additional countries in the EU, UK, Switzerland, and Australia, which could translate into incrementally larger royalty revenue in the quarters ahead.
Market PenetrationQ2 achieved a record number of new enrollments for Briumvi since its ~2.5 years on the market, indicating the product's growing dynamic market capture.
Bears Say
Product CompetitionTG’s subq option is behind relative to approved subq options and may ultimately face an uphill battle in what is viewed as a growing section of the MS population.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $21.16 and its highest was $46.48 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $5.55B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 35 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Aug 04, 2025. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.211 by -$0.041.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.22.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 158,665,620 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.17 in its last earnings report, missing expectations of $0.211. Following the earnings report the stock price went down -17.99%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$38.25 (7.53% Upside)
$38.25 (7.53% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $672.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.98%
12-Months-Change
Fundamentals
Return on Equity
26.63%
Trailing 12-Months
Asset Growth
75.12%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong quarter for TG Therapeutics, marked by significant revenue growth, successful product adoption, and strategic pipeline advancements. However, increased operating expenses and potential market challenges are areas of concern.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$38.25
▲(7.53% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
9.80% Insiders
18.66% Mutual Funds
10.76% Other Institutional Investors
38.35% Public Companies and Individual Investors